MediWound is an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. MediWound was founded in 2000 and is headquartered in Yavne, Israel.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
MediWound news
17.05.2022
MediWound's IFRS loss for 3 months of 2022 was $3.589 million, up 25.9% from $2.851 million in the previous year. Revenue decreased by 24.6% to $4.407 million compared to $5.847 million a year earlier.
Source: 
ir.mediwound.com
ir.mediwound.com
17.03.2022
MediWound's GAAP loss for 2021 was $4.16 million, up 2.4 times from $1.732 million in the previous year. Revenue fell 17.8% to $5.487 million from $6.673 million a year earlier.
Source: ir.mediwound.com
ir.mediwound.com
17.11.2021
MediWound's GAAP loss for 9M 2021 was $9.391 million, up 25.8% from $7.464 million in the prior year. Revenue increased 21.1% to $18.276 million from $15.09 million a year earlier.
Source: ir.mediwound.com
ir.mediwound.com
10.08.2021
MediWound' IFRS loss for 6M 2021 was $6.046 million, up 8.8% from $5.557 million in the previous year. Revenue increased 40.6% to $11.904 million from $8.465 million a year earlier.
Source: ir.mediwound.com
ir.mediwound.com
General information
| Company name | MediWound |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 42 Hayarkon Street Yavne, 8122745 Israel |
| Mailing address | 42 Hayarkon Street Yavne, 8122745 Israel |
| Website | ir.mediwound.com |
| Information disclosure | www.sec.gov |
English (US) 